Immobilized doxorubicin and ribociclib carbamate linkers encaged in surface modified cubosomes spatially target tumor reductive environment to enhance antitumor efficacy
Source abstract
Abstract
In the present investigation, we have strategically synthesized Glutathione (GSH) stimuli-sensitive analogues using carbamate linkers (CL) of DOX (DOX-CL) and RB (RB-CL) which were then anchored to gold nanoparticles (Au-DOX-CL, Au-RB-CL) using mPEG as a spacer. It was observed that carbamate linkage (CL) with four carbon spacer is critical, to position the terminal thiol group, to access the carbamate group efficiently to achieve GSH-assisted release of DOX and RB in tumor-specific environment. When assessed for GSH reductase activity in MDA-MB 231 cell lines, Au-DOX-CL and Au-RB-CL showed nearly 4.18 and 3.13 fold higher GSH reductive activity as compared to the control group respectively. To achieve spatial tumor targeting with a high payload of DOX and RB, Au-DOX-CL and Au-RB-CL were encapsulated in the cell-penetrating peptide (CPP) modified liquid crystalline cubosomes i.e. CPP-Cu(Au@CL-DR). After internalization, the prototype nanocarriers release respective drugs at a precise GSH concentration inside the tumor tissues, amplifying drug concentration to a tune of five-fold. The drug concentrations remain within the therapeutic window for 72 h with a significant reduction of RB (7.8-fold) and DOX (6-fold) concentrations in vital organs, rendering reduced toxicity and improved survival. Overall, this constitutes a promising chemotherapeutic strategy against cancer and its potential application in the offing.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · Peptidase Inhibition and Analysis · Neuropeptides and Animal Physiology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (41)
Show source-provided references
1. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis10.1016/j.gendis.2018.05.001 ↗
2. Breast cancer10.1016/j.ygyno.2014.01.022 ↗
3. Triple-negative breast cancer therapy: current and future perspectives (review)10.3892/ijo.2020.5135 ↗
4. Weberding · 2018
5. Latest developed strategies to minimize the off-target effects in CRISPR-Cas-mediated genome editing10.3390/cells9071608 ↗
6. Making smart drugs smarter: the importance of linker chemistry in targeted drug delivery10.1002/med.21720 ↗
7. Treating prostate cancer by antibody-drug conjugates10.3390/ijms22041551 ↗
8. Monodisperse gold nanoparticles: a review on synthesis and their application in modern medicine10.3390/ijms23137400 ↗
9. Gold nanoparticle surface engineering strategies and their applications in biomedicine and diagnostics10.1007/s13205-019-1577-z ↗
10. Controlled drug delivery vehicles for cancer treatment and their performance
11. A review on the synthesis and functionalization of gold nanoparticles as a drug delivery vehicle10.2147/IJN.S279094 ↗
12. Gold nanoparticle-mediated delivery of paclitaxel and nucleic acids for cancer therapy (review)10.3892/mmr.2020.11580 ↗
13. Glutathione/pH-responsive nanosponges enhance strigolactone delivery to prostate cancer cells10.18632/oncotarget.26287 ↗
14. Stimuli-responsive liposomes for drug delivery10.1002/wnan.1450 ↗
15. Review of the methodologies used in the synthesis gold nanoparticles by chemical reduction10.1016/j.jallcom.2019.05.153 ↗
16. Measurement of glutathione as a tool for oxidative stress studies by high performance liquid chromatography10.3390/molecules25184196 ↗
17. Gold nanoparticles grafted by reduced glutathione with thiol function preservation10.1016/j.colcom.2016.07.002 ↗
18. Preparation of cubosomes containing gold nanoparticles and drug release behavior under light irradiation10.1016/j.jconrel.2013.08.131 ↗
19. In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting10.1016/j.apsb.2014.12.001 ↗
20. Nanoparticles modified with cell-penetrating peptides: conjugation mechanisms, physicochemical properties, and application in cancer diagnosis and therapy10.3390/ijms21072536 ↗
21. Insights into cell penetrating peptide conjugated gold nanoparticles for internalization into bacterial cells10.1016/j.bpc.2018.03.005 ↗
22. Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression10.1039/C9BM00221A ↗
23. P-gp modulatory acetyl-11-keto-β-boswellic acid based nanoemulsified carrier system for augmented oral chemotherapy of docetaxel10.1016/j.colsurfb.2017.04.028 ↗
24. Recent therapeutic trends and promising targets in triple negative breast cancer10.1016/j.pharmthera.2019.02.006 ↗
25. A. Bandyopadhyay, L. Wang, J. Agyin, Y. Tang, S. Lin, I.-T. Yeh, K. De, L.-Z. Sun, Doxorubicin in Combination With a Small TGFb Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models, (n.d.). doi:https://doi.org/10.1371/journal.pone.0010365.10.1371/journal.pone.0010365 ↗
26. Theranostic lyotropic liquid crystalline nanostructures for selective breast cancer imaging and therapy10.1016/j.actbio.2020.06.023 ↗
27. Amalgamated microneedle array bearing ribociclib-loaded transfersomes eradicates breast cancer via CD44 targeting10.1021/acs.biomac.1c01076 ↗
28. Doxorubicin differentially induces apoptosis, expression of mitochondrial apoptosis-related genes, and mitochondrial potential in BCR-ABL1-expressing cells sensitive and resistant to imatinib10.1155/2015/673512 ↗
29. Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastoma10.1007/s12645-010-0006-0 ↗
30. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms: intermediacy of H2O2- and p53-dependent pathways10.1074/jbc.M400944200 ↗
31. In vitro study of a pH-sensitive multifunctional doxorubicin-gold nanoparticle system: therapeutic effect and surface enhanced Raman scattering10.1039/C5RA09872F ↗
32. Synthesis, characterization, cellular uptake, and in vitro anticancer activity of fullerenol-doxorubicin conjugates10.3389/fphar.2020.598155 ↗
33. Cellular uptake, intracellular trafficking, and antitumor efficacy of doxorubicin-loaded reduction-sensitive micelles10.1016/j.biomaterials.2013.01.101 ↗
34. Ormeloxifene-induced unfolded protein response contributes to autophagy-associated apoptosis via disruption of Akt/mTOR and activation of JNK
35. Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles10.1016/j.jconrel.2011.01.021 ↗
36. Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model10.1016/j.biopha.2018.11.011 ↗
37. Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity10.1021/mp5000373 ↗
38. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies10.1053/j.seminoncol.2004.08.002 ↗
39. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in nude mice10.1007/BF00434396 ↗
40. Co-administration of imipramine and doxorubicin reduces the survival rate and body weight of mice
41. Preclinical toxicological study of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in synergic ratio10.1016/j.biopha.2021.112307 ↗